Citations

Showing 10 of 108119 citations.

Association between initial opioid use and response to a brief interdisciplinary treatment program in fibromyalgia
Oh, Terry H., Park, Donghwi , Kim, Chul‐Hyun , Hwang, Jong-Moon , Lee, Byung‐Joo

Mayo Clinic

Medicine | January 4, 2019 | Volume: 98 | Issue: 1 | Pages: e13913

10.1097/md.0000000000013913 | PMID 30608417 Get It

Abstract Background: To evaluate the association between opioid use and treatment outcome (symptom severity, quality of life [QOL]) after a brief interdisciplinary fibromyalgia treatment program (FTP). Method: Subjects (n = 971) with fibromyalgia participated in the FTP. They filled out the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline and 6 to 12 months after the FTP. Post-treatment changes in FIQ and SF-36 scores were compared after stratifying the participants into opioid user and non-opioid user groups. Results: A total of 236 patients (24.3%) were opioid users. Compared with non-opioid users, the opioid users had worse symptom severity measured using FIQ total score (p < .001) and all subscales at baseline and post treatment, as well as worse QOL measured using all SF-36 subscales and physical and mental components. Comparison of least-square means of mean change of QOL between opioid users and non-opioid users after analysis of covariance adjusted patient characteristics and baseline scores showed that the FIQ subscale scores of physical impairment (p < .05), job ability (p < .05), and fatigue (p < .05) were significantly less improved in the opioid users compared with the non-opioid users. Moreover, the SF-36 subscale score of general health perception (p < .05) was significantly less improved in the opioid users compared with non-opioid users. However, post-treatment changes in mean scores for QOL subscale generally did not significantly differ in both groups. Conclusions: Opioid use did not affect response to the FTP, as measured using the FIQ total score or SF-36 physical and mental component summary scores. Furthermore, the opioid user group showed less improvement in the FIQ subscale scores of physical impairment, job ability, and fatigue and in the SF-36 subscale scores of general health perception.
Pain-induced peripheral artery tonometry scores in the control arm are impaired in patients with apical ballooning syndrome
Sun, Tao , Matsuzawa, Yasushi , Lennon, Ryan J. , Park, Kyoung H., Lerman, Lilach O. , Widmer, R. Jay , Lennon, Ryan J. , Lerman, Amir

Mayo Clinic

Medicine | January 4, 2019 | Volume: 98 | Issue: 1 | Pages: e13841

10.1097/md.0000000000013841 | PMID 30608400 Get It

Abstract Mental and physical stress is thought to play an important causative factor in apical ballooning syndrome (ABS) likely secondary to the vasomotor dysfunction. However, there are currently few data related to the impact of physical stress in this unique cardiomyopathy. A total 18 patients, including 8 females with history of ABS and 10 post-menopausal controls, underwent physical and mental tests. Assessments included the pain-induced peripheral artery tonometry scores (PIPATs) and mental stress peripheral artery tonometry scores (PATs). Compared with control group, PIPATs were significantly attenuated in patients with ABS in both baseline and post-mental stress (0.94 ± 0.08 vs1.30 ± 0.54, P <.05 and 0.87 ± 0.19 vs1.24 ± 0.21 P = .01, respectively); mental stress PATs were significantly lower in patients with ABS, both in Stroop test (0.79 ± 0.30 vs 1.24 ± 0.43, P = .01) and arithmetic test (0.91 ± 0.27 vs 1.36 ± 0.57, P = .01). PIPATs correlated significantly with mental stress PATs, both in arithmetic and Stroop test (P <.05). The PIPATs were attenuated in female with history of ABS and the vascular response to pain may provide a different pathogenesis mechanism on detecting patients with ABS.
Patient-derived xenografts from breast cancer patients before and after neoadjuvant chemotherapy: A prospective study.
Yu, Jia , Gao, Bowen , Moyer, Ann M. , Visscher, Daniel W., Conners, Amy Lynn , Dockter, Travis , Jones, Katie N., McLaughlin, Sarah A. , Copland, John A. , Moreno‐Aspitia, Alvaro , Northfelt, Donald W. , Gray, Richard J. , Weinshilboum, Richard M. , Wang, Liewei , Boughey, Judy C. , Yin, Ping , Sinnwell, Jason P. , Kalari, Krishna R. , Suman, Vera J. , Weinshilboum, Richard M. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 11130-11130

10.1200/jco.2014.32.15_suppl.11130 Get It

An exhaustive algorithm for detecting copy number aberrations and large structural variants in whole-genome, mate-pair sequencing data.
Asmann, Yan W. , Necela, Brian M. , Chen, Xianfeng , Kocher, Jean‐Pierre , Feldman, Andew L., Novak, Anne J. , Perez, Edith A. , Thompson, E. Aubrey , Wang, Chen , Maurer, Matthew J. , Habermann, Thomas M. , Slager, Susan L. , Doǧan, Ahmet , Cerhan, James R.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e22171-e22171

10.1200/jco.2014.32.15_suppl.e22171 Get It

Prognostic value of pathologic tumor response in ewing sarcoma (ES).
Keeney, M.G., Fritchie, Karen , Folpe, Andrew L. , Ahmed, Safia K. , Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e21022-e21022

10.1200/jco.2014.32.15_suppl.e21022 Get It

A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
Chuk, Meredith K. , Widemann, Brigitte C. , Ahern, Charlotte H., Wright, John Joseph, Fox, Elizabeth , Weigel, Brenda J. , Blaney, Susan M. , Reid, Joel M. , Kim, AeRang , Lodish, Maya Beth

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 10078-10078

10.1200/jco.2014.32.15_suppl.10078 Get It

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
Polish, Ariel, Abbinanti, Susan, Vintilescu, Claudia Roxana, Rademaker, Alfred , Humphreys, Catherine, Cehic, Rasima, McFarland, Thomas, Tine, Brian Andrew Van, Okuno, Scott H. , Agulnik, Mark , Nye, Lauren Elizabeth , Humphreys, Catherine, Milhem, Mohammed , Skubitz, Keith M.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS10604-TPS10604

10.1200/jco.2014.32.15_suppl.tps10604 Get It

Mitomycin C, doxorubicin, and cisplatin: as a safe and effective preoperative chemoradiation cocktail for soft tissue sarcomas.
Petersen, Ivy A. , Rose, Peter S. , Fritchie, Karen , Okuno, Scott H. , Sridharan, Meera , Robinson, Steven I.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 10593-10593

10.1200/jco.2014.32.15_suppl.10593 Get It

Alliance A091102: Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson, Mark A. , Mahoney, Michelle R., Tap, William D. , Keohan, Mary Louise , Tine, Brian Andrew Van, Agulnik, Mark , Horvath, Laura E., D'Angelo, Sandra P , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 10527-10527

10.1200/jco.2014.32.15_suppl.10527 Get It

Scrambler therapy for treatment of chemotherapy-induced peripheral neuropathy.
Weisbrod, Breanna L., Pachman, Deirdre R. , Seisler, Drew K., Barton, Debra L. , Fee-Schroeder, Kelliann C., Liu, Heshan , Loprinzi, Charles L. , Smith, Thomas J. , Lachance, Daniel Honore , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9622-9622

10.1200/jco.2014.32.15_suppl.9622 Get It